Abstract
KB-R7943 (2-[2-[4-(4-nitrobenzyloxy)phenyl]ethyl]isothiourea methanesulfonate) is a potent and selective Na+/Ca2+ exchange (NCX) inhibitor that is 3-fold more inhibitory to NCX3 than to NCX1 or NCX2. Here we searched for amino acid residues that may form the KB-R7943 receptor in the exchanger by analyzing the function of chimeras between NCX1 and NCX3 as well as of their site-directed mutants. We found that the highly conserved α-2 repeat of the exchanger is almost exclusively responsible for the difference in drug response of the isoforms. Such difference was mostly reproduced by single substitutions of residues in the α-2 repeat (V820G or Q826V in NCX1 and A809V or A809I in NCX3), suggesting their importance in drug sensitivity. Cysteine scanning mutagenesis of the α-2 repeat of NCX1 identified one residue (Gly833) that caused a large (≥ 30-fold) reduction in drug sensitivity. We found that the Gly-to-Thr substitution caused even larger reduction in drug sensitivity. Interestingly, extracellularly applied KB-R7943 at 0.8 μM markedly inhibited the whole-cell outward exchange current, whereas the drug applied intracellularly at 30 μM did not. These results suggest that KB-R7943 inhibits the exchanger from the external side in intact cells and that a region of the α-2 repeat of NCX1 containing Gly833 may participate in the formation of the drug receptor. Because we suggested previously that Gly833 is accessible from the inside of a cell, the results raised an interesting possibility that this residue may alter its position during Na+/Ca2+ exchange in such a way that it becomes accessible to external drug.
Footnotes
- Received September 28, 2000.
- Accepted November 22, 2000.
-
Send reprint requests to: Dr. Munekazu Shigekawa, Department of Molecular Physiology, National Cardiovascular Center Research Institute, Fujishiro-dai 5, Suita, Osaka 565-8565, Japan. E-mail: shigekaw{at}ri.ncvc.go.jp
-
This work was supported by Grants-in-Aid for Scientific Research [10470013 (M.S.) and 12670102 (T.I.)] from the Ministry of Education, Science and Culture of Japan; Research Grant for Cardiovascular Diseases (11-C) from the Ministry of Health and Welfare (M.S.); and grants from the Uehara Memorial Foundation (M.S.), the Mochida Memorial Foundation (T.I.), and the Japan Cardiovascular Research Foundation (T.I.).
- The American Society for Pharmacology and Experimental Therapeutics
MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years.Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page.
|